Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

American Journal of Hematology

Volumn 79, Issue 4, 2005, Pages 319-328

  Gertz, Morie A ^a   Comenzo, Ray ^b   Falk, Rodney H ^c   Fermand, Jean Paul ^d   Hazenberg, Bouke P ^e   Hawkins, Philip N ^f   Merlini, Giampaolo ^g   Moreau, Philippe ^h   Ronco, Pierre ⁱ   Sanchorawala, Vaishali ^c   Sezer, Orhan ^j   Solomon, Alan ^k   Grateau, Giles ^l  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF PAVIA   (Italy)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL TENON   (France)

^j HUMBOLDT UNIVERSITY   (Germany)

^k UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^l HÔTEL DIEU   (France)

more..

Author keywords

Amyloid, organ involvement; Amyloid, response to treatment; Primary systemic amyloidosis

Indexed keywords

AMYLOID P COMPONENT; APROTININ; COLCHICINE; CORTICOSTEROID; DEXAMETHASONE; DIMETHYL SULFOXIDE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; RADIOISOTOPE; TECHNETIUM 99M; VINCRISTINE;

AMYLOIDOSIS; AUTONOMIC NEUROPATHY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ELECTROMYOGRAPHY; ENDOSCOPIC BIOPSY; GASTROINTESTINAL DISEASE; HEART AMYLOIDOSIS; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY FUNCTION; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION; NERVE CONDUCTION; NERVE FUNCTION; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SOFT TISSUE DISEASE; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

AMYLOID; AMYLOIDOSIS; FRANCE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; ORGAN SPECIFICITY;

EID: 23244448608     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20381     Document Type: Conference Paper

References (101)

1. Hanai N, Ishihara T, Uchino F, Imada N, Fujihara S, Ikegami J. Effects of dimethyl sulfoxide and colchicine on the resorption of experimental amyloid. Virchows Arch A Pathol Anat Histol 1979;384:45-52.
2. Ravid M, Keizman IK, Sohar E. Effect of a single dose of dimethyl sulphoxide on renal amyloidosis. Lancet 1977;1:730-731.
3. Comenzo RL. Primary systemic amyloidosis. Curr Treat Options Oncol 2000;1:83-89.
4. Sezer O, Schmid P, Shweigert M, et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999;23:967-969.
5. Ronco P, Aucouturier P, Mougenot B. Plasma cell dyscrasia-related glomerulopathies and Fanconi's syndrome: a molecular approach. J Nephrol 2000;13(Suppl 3):S34-S44.
6. Ronco PM, Aucouturier P. The molecular bases of plasma cell dyscrasia-related renal diseases. Nephrol Dial Transplant 1999; 14(Suppl 1):4-8.
7. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-259.
8. Comenzo RL, Sanchorawala V, Fisher C, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999;104:553-559.
9. Sanchorawala V, Wright DG, Seldin DC, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002;117:886-889.
10. Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN. Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis [abstract]. Blood 2004;104:216a (abstract no. 755).
11. Sezer O, Niemoller K, Jakob C, Langelotz C, Eucker J, Possinger K. Novel approaches to the treatment of primary amyloidosis. Expert Opin Invest Drugs 2000;9:2343-2350.
12. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol 2000;130:88-98.
13. Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration: analysis of four years' experience. Am J Med 1987;82:412-414.
14. Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22:1393-1401.
15. Hawkins PN, Aprile C, Capri G, et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 1998;25:701-708.
16. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11:649-655.
17. van Gameren II, Hazenberg BP, Jager PL, Smit JW, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002;9:165-174.
18. Looi LM. The pattern of amyloid deposition in the lung. Malays J Pathol 1999;21:29-35.
19. al-Ratrout JT, Satti MB. Primary localized cutaneous amyloidosis: a clinicopathologic study from Saudi Arabia. Int J Dermatol 1997;36:428-434.
20. Hamidi Asl K, Liepnieks JJ, Nakamura M, Benson MD. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 1999;162:5556-5560.
21. Malek RS, Wahner-Roedler DL, Gertz MA, Kyle RA. Primary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy. J Urol 2002;168:1018-1020.
22. Lee HM, Naor J, DeAngelis D, Rootman DS. Primary localized conjunctival amyloidosis presenting with recurrence of subconjunctival hemorrhage. Am J Ophthalmol 2000;129:245-247.
23. Borodic GE, Beyer-Machule CK, Millin J, Conte J, Foster CS. Immunoglobulin deposition in localized conjunctival amyloidosis. Am J Ophthalmol 1984;98:617-622.
24. Goldsmith JD, Lai ML, Daniele GM, Tomaszewski JE, LiVolsi VA. Amyloid goiter: report of two cases and review of the literature. Endocr Pract 2000;6:318-323.
25. Piazza C, Cavaliere S, Foccoli P, Toninelli C, Bolzoni A, Peretti G. Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of 32 patients. Eur Arch Otorhinolaryngol 2003;260:349-354.
26. Pucci A, Wharton J, Arbustini E, et al. Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity. J Pathol 1991;165:235-241.
27. Rumpelt HJ, Braun A, Spier R, Suren EG, Thies E. Localized amyloid in the menisci of the knee joint. Pathol Res Pract 1996;192:547-551.
28. Alhanasou NA, West L, Sallie B, Puddle B. Localized amyloid deposition in cartilage is glycosaminoglycans-associated. Histopathology 1995;26:267-272.
29. Ustun MO, Ekinci N, Payzin B. Extramedullary plasmacytoma of the parotid gland: report of a case with extensive amyloid deposition masking the cytologic and histopathologic picture. Acta Cytol 2001;45:449-453.
30. Kyle RA, Gertz MA, Linke RP. Amyloid localized to tenosynovium at carpal tunnel release: immunohistochemical identification of amyloid type. Am J Clin Pathol 1992;97:250-253.
31. Eulitz M, Weiss DT, Solomon A. Immunoglobulin heavy-chain-associated amyloidosis. Proc Natl Acad Sci USA 1990;87: 6542-6546.
32. Perfetti V, Garini P, Vignarelli MC, Marinone MG, Zorzoli I, Merlini G. Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica 1995;80:409-415.
33. Sezer O, Eucker J, Jakob C, Possinger K. Diagnosis and treatment of AL amyloidosis. Clin Nephrol 2000;53:417-423.
34. Katzmann JA, Dispenzieri A, Abraham RS, Kyle RA. Performance of free light chain assays in clinical practice [abstract]. Blood 2004;104:216a (abstract no. 757).
35. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569.
36. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791.
37. Wall J, Solomon A. Flow cytometric characterization of amyloid fibrils. Methods Enzymol 1999;309:460-466.
38. Gillmore JD, Booth DR, Madhoo S, Pepys MB, Hawkins PN. Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant 1999;14:2639-2644.
39. Hawkins PN. Hereditary systemic amyloidosis with renal involvement. J Nephrol 2003;16:443-448.
40. Grateau G. What has become of inflammatory amyloidosis? Rev Prat 2003;53:516-519 [in French].
41. Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 1986;29:376-385.
42. Gillmore JD, Booth DR, Pepys MB, Hawkins PN. Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart 1999;82:e2.
43. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002;9:108-114.
44. Anesi E, Palladini G, Perfetti V, Arbustini E, Obici L, Merlini G. Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 2001;111:243-244.
45. Haagsma EB, Scheffer H, Altland K, De Jager AE, Hazenberg BP. Transthyretin Val71Ala mutation in a Dutch family with familial amyloidotic polyneuropathy. Amyloid 2000;7:218-221.
46. Valleix S, Drunat S, Philit JB, et al. Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int 2002;61:907-912.
47. Kaplan B, Hrncic R, Murphy CL, Gallo G, Weiss DT, Solomon A. Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue. Methods Enzymol 1999;309:67-81.
48. Kaplan B, Murphy CL, Ratner V, Pras M, Weiss DT, Solomon A. Micro-method to isolate and purify amyloid proteins for chemical characterization. Amyloid 2001;8:22-29.
49. Murphy CL, Eulitz M, Hrncic R, et al. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001;116:135-142.
50. Lim A, Prokaeva T, McComb ME, et al. Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis. Anal Chem 2002;74:741-751.
51. Yamashita T, Ando Y, Bernt Suhr O, et al. A new diagnostic procedure to detect unknown transthyretin (TTR) mutations in familial amyloidotic polyneuropathy (FAP). J Neurol Sci 2000;173: 154-159.
52. Bergen HR III, Zeldenrust SR, Butz ML, et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 2004;50:1544-1552 [Epub 2004 Jun 24].
53. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-4282.
54. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001;28:637-642.
55. Albright R, Brensilver J, Cortell S. Proteinuria in congestive heart failure. Am J Nephrol 1983;3:272-275.
56. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000;45:107-137.
57. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982;49:9-13.
58. Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine 2002;69:538-545.
59. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107:2446-2452.
60. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107: 2440-2445.
61. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-1789.
62. Tabbibizar R, Maisel A. The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr Opin Cardiol 2002;17:340-345.
63. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003;82: 291-298.
64. Reilly MM, Staunton H. Peripheral nerve amyloidosis. Brain Pathol 1996;6:163-177.
65. Haan J. Amyloid and peripheral nervous system disease [letter to the editor]. Clin Neurol Neurosurg 1994;96:332.
66. Olmer M, Berland Y, Purgus R, Schultz G. Determination of blood volume in nephrotic patients. Am J Nephrol 1989;9:211-214.
67. Sezer O, Eucker J, Schmid P, Possinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 2000;79:1-6.
68. Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 1997;80:1242-1245.
69. Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002;23:157-161.
70. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998;104:232-237.
71. Tada S, Iida M, Yao T, Kitamoto T, Yao T, Fujishima M. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993;34:1412-1417.
72. Tada S, Iida M, Yao T, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc 1994;40:45-50.
73. Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis: the Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996;124:407-413.
74. Celli BR, Rubinow A, Cohen AS, Brody JS. Patterns of pulmonary involvement in systemic amyloidosis. Chest 1978;74: 543-547.
75. Berk JL, Keane J, Seldin DC, et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003;124:969-977.
76. Keith DA. Oral features of primary amyloidosis. Br J Oral Surg 1972;10:107-115.
77. Fautrel B, Fermand JP, Sibilia J, Nochy D, Rousselin B, Ravaud P. Amyloid arthropathy in the course of multiple myeloma. J Rheumatol 2002;29:1473-1481.
78. Schneider BF, Normansell D, Ayers CR, Hess CE. Intermittent claudication as the presenting symptom in primary amyloidosis. Acta Haematol 1993;90:106-107.
79. Kyriakides T, Marquez B, Panousopoulos A, Kyriacou E, Kyriacou K. Amyloid myopathy: evidence for mechanical injury to the sarcolemma. Clin Neuropathol 2002;21:145-148.
80. Robert C, Aractingi S, Prost C, et al. Bullous amyloidosis: report of 3 cases and review of the literature. Medicine (Baltimore) 1993; 72:38-44.
81. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123.
82. Fermand JP, Brechignac S. The role of autologous stem cell transplantation in the management of multiple myeloma. Pathol Biol (Paris) 1999;47:199-202.
83. Grateau G. Amyloidosis physiopathology. Joint Bone Spine 2000;67:164-170.
84. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74-82.
85. Trotter JL, Engel WK, Ignaczak FI. Amyloidosis with plasma cell dyscrasia: an overlooked cause of adult onset sensorimotor neuropathy. Arch Neurol 1977;34:209-214.
86. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26:770-776;
87. erratum, Diabetes Care 2003;26:2227.
88. Dyck PJ, Melton LJ III, O'Brien PC, Service FJ. Approaches to improve epidemiological studies of diabetic neuropathy: insights from the Rochester Diabetic Neuropathy Study. Diabetes 1997;46(Suppl 2):S5-S8.
89. Kim SH, Han JK, Lee KH, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol 2003;58:610-620.
90. Miyata M, Sato N, Watanabe H, et al. Magnetic resonance imaging findings in primary amyloidosis-associated arthropathy. Intern Med 2000;39:313-319.
91. Jensen RL, Crapo RO. Diffusing capacity: how to get it right. Respir Care 2003;48:777-782.
92. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136.
93. Attaelmannan M, Levinson SS. Understanding and identifying monoclonal gammopathies. Clin Chem 2000;46:1230-1238.
94. Marshall T, Williams KM. Electrophoretic analysis of Bence Jones proteinuria. Electrophoresis 1999;20:1307-1324.
95. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491.
96. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
97. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-278.
98. Kyle RA. Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med 1999;123:114-148.
99. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-1444.
100. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680.
101. Tate JR, Gill D, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49:1252-1257.